Ikemura T, Ohmori K, Tanaka T, Matsuda Y, Kitamura S
Pharmaceutical Research Laboratories, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
J Pharm Pharmacol. 1996 Jan;48(1):100-5. doi: 10.1111/j.2042-7158.1996.tb05886.x.
The effects of an endothelin (ET)-receptor B-specific antagonist, RES-701-1, on ET-induced contraction of guinea-pig trachea and on ET-induced bronchoconstriction in anaesthetized guinea-pigs were investigated. In the epithelium-removed tracheal preparation, 1 x 10(-5) M RES-701-1 inhibited contractions induced by the ETB-specific agonist sarafotoxin S6c (pKB = 6.10). In the epithelium-intact tracheal preparation, RES-701-1 (1 x 10(-5) M)inhibited the ET-3-induced contraction (pKB = 5.27), but enhanced the ET-1-induced contraction significantly and shifted the concentration-response curve to the left. The maximal responses of ET-1- and ET-3-induced contraction were augmented by epithelium removal by 1.5 and 1.8-fold, respectively. Against ET-3-induced contraction in the tracheal preparation without epithelium, RES-701-1 (0.3-10 x 10(-6)M) antagonized the contraction in a concentration-dependent manner (pA2 = 5.9). On the other hand, RES-701-1 (1 x 10(-5)M) did not affect ET-1-evoked responses in the trachea without epithelium. The intravenous administration of ET-1 (1.5 nmol/kg-1) or ET-3 (1.5 nmol/kg-1) evoked a biphasic, fast and sustained bronchoconstriction in anaesthetized guinea-pigs pretreated with propranolol (1.0 mg/kg-1). when administered intravenously, RES-701-1 (0.3 or 1.0 mg/kg-1) showed significant reduction in both phases of bronchoconstriction induced by ET-3. As in the case of ET-1-induced bronchoconstriction, rES-701-1 augmented the sustained phase although a significant reduction of the fast phase was observed. These results indicate that RES-701-1 can inhibit the ET-3 induced airway responses not only in-vitro but also in-vivo.
研究了内皮素(ET)受体B特异性拮抗剂RES-701-1对ET诱导的豚鼠气管收缩以及对麻醉豚鼠ET诱导的支气管收缩的影响。在去除上皮的气管标本中,1×10⁻⁵ M RES-701-1抑制ETB特异性激动剂沙拉新(pKB = 6.10)诱导的收缩。在完整上皮的气管标本中,RES-701-1(1×10⁻⁵ M)抑制ET-3诱导的收缩(pKB = 5.27),但显著增强ET-1诱导的收缩并使浓度-反应曲线左移。去除上皮后,ET-1和ET-3诱导收缩的最大反应分别增加了1.5倍和1.8倍。在无上皮的气管标本中,针对ET-3诱导的收缩,RES-701-1(0.3 - 10×10⁻⁶ M)以浓度依赖性方式拮抗收缩(pA2 = 5.9)。另一方面,RES-701-1(1×10⁻⁵ M)不影响无上皮气管中ET-1诱发的反应。静脉注射ET-1(1.5 nmol/kg⁻¹)或ET-3(1.5 nmol/kg⁻¹)在预先用普萘洛尔(1.0 mg/kg⁻¹)预处理的麻醉豚鼠中诱发双相、快速和持续的支气管收缩。静脉注射RES-701-1(0.3或1.0 mg/kg⁻¹)时,ET-3诱导的支气管收缩的两个阶段均显著减轻。与ET-1诱导的支气管收缩情况一样,尽管快速阶段显著减轻,但RES-701-1增强了持续阶段。这些结果表明,RES-701-1不仅在体外而且在体内均可抑制ET-3诱导的气道反应。